ImprimisRx Recalls Curcumin Emulsion Injection Due to Undeclared Excipient
ImprimisRx is recalling Curcumin Emulsion 10mg/ml Injection vials because non-pharmaceutical grade PEG 40 Castor Oil was used due to supplier mislabeling.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the use of non-pharmaceutical grade excipients in an injectable medication presents a significant risk of adverse health consequences, aligning with the 'Severe' criteria for significant injury reports or high-risk defects.
Plain-English summary
ImprimisRx CA, Inc., dba ImprimisRx, is recalling 2,608 vials of Curcumin Emulsion 10mg/ml Injection, Sterile 10 mL Multiple Dose Vial, For Slow IV Administration. The product was compounded for licensed professional or patient use and distributed nationwide.
The recall was initiated because non-pharmaceutical grade PEG 40 Castor Oil was used in the product due to a mislabeling error by the supplier. This resulted in an incorrect or undeclared excipient in the final compounded medication.
Patients and healthcare providers who have received or administered these specific vials should stop using them and contact ImprimisRx for further instructions. The affected lots are identified by specific lot codes and expiration dates ranging from June 19, 2017, to July 23, 2017.
The recalled product
- Product
- Curcumin Emulsion 10mg/ml Injection, Sterile 10 mL Multiple Dose Vial, For Slow IV Administration, Compounded for a licensed professional or patient use by ImprimisRx, Irvine, CA
- Manufacturer
- ImprimisRx CA, Inc., dba ImprimisRx
- Category
- Drug — Compounded Injectable
- Affected units
- 2,608
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- 03212017@21B Exp:6/19/2017
- 03232017@19B Exp:6/21/2017
- 03292017@27B Exp:6/27/2017
- 03292017@9B Exp:6/27/2017
- 04042017@21B Exp:7/3/2017
- 04122017@22B Exp:7/11/2017
- 04132017@14B Exp:7/12/2017
- 04192017@37B Exp:7/18/2017
- 04192017@17B Exp:7/18/2017
- 04242017@18B Exp:7/23/2017
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by ImprimisRx CA, Inc., dba ImprimisRx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · ImprimisRx CA, Inc., dba ImprimisRx
See all →- ModerateImprimisRx Recalls Latanoprost Ophthalmic Drops Due to Undeclared Excipient
FDA (Drugs) · 2017-09-13
- ModerateImprimisRx Recalls Timolol-Latanoprost Ophthalmic Drops Due to Mislabeling
FDA (Drugs) · 2017-09-13
- SevereImprimisRx Recalls Timolol Ophthalmic Drops Due to Undeclared Excipient
FDA (Drugs) · 2017-09-13
Same hazard · undeclared excipient
See all →- CriticalLubrisine eye drops recalled for undeclared colloidal silver and sterility issues
FDA (Drugs) · 2018-12-26
- ModerateRanbaxy Recalls Absorica LD Isotretinoin Capsules Due to Undeclared Dye
FDA (Drugs) · 2015-08-12
- CriticalPharmakon Recalls Midazolam HCl Vials Due to Undeclared Benzyl Alcohol
FDA (Drugs) · 2014-09-03
- SeverePharmakon Recalls Midazolam IV Bags Due to Undeclared Benzyl Alcohol
FDA (Drugs) · 2014-09-03
Similar recalls
- LowLupin Recalls Ceftriaxone Injection Vials Due to CGMP Deviations
FDA (Drugs) · 2016-06-08
- SevereImprimis Recalls Dexamethasone-Moxifloxacin Injection Due to Sterility Concerns
FDA (Drugs) · 2021-01-06
- HighFDA Recalls Injectable Medication Due to Sterility Assurance Failure
FDA (Drugs) · 2022-09-21
- LowPharmedium Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2018-04-25
- HighCompounded Tirzepatide Injectable Vials Recalled for Sterility Assurance Issues
FDA (Drugs) · 2024-09-11
- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16